RxDoctor Payments Data

Krishna Venkatesh, MD

Colon & Rectal Surgery · Gilbert, AZNPI 1689878472

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (42.2%), education and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Intuitive Surgical at 44.9% of the total. Reporting peaked in 2020 at $6,554 and has fallen 97.5% since, to $162 in 2025.

$13,992in general payments, 2019–2025

Across 104 payments — averaging $134.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$6K
  • Covidien LP$6K
  • Merck$391
  • Coloplast$330
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$147
  • Johnson & Johnson$120
  • plus $806 from 22 others

What the payments were for

  • Speaking & faculty fees$5,90042%
  • Travel & lodging$510%
  • Food & beverage$2,42317%
  • Education$5,55940%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,992 in reported general payments places this provider in the 65th percentile of 50 colon & rectal surgery providers in Arizona.

See all colon & rectal surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$114,908
Medicare patients
301
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates50$3,359
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,597
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg99$1,975
CholestyramineCholestyramine (With Sugar)17$955
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl45$736
Budesonide DrBudesonide11$542
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl33$540
Hydrocortisone29$481
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$224
Oxycodone Hcl17$118
Metronidazole51$91
Ondansetron Hcl11$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$101$2,59716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 50 colon & rectal surgery providers in Arizona.

Other colon & rectal surgery in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →